Clinical trials: QTc Interval
Qt Interval, Variation in
Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib
This study is conducted to evaluate effect on QT/QTc Interval after multiple dose of celecoxib among healthy adult volunteers. It is randomized, open-label, negative and postive control, and crossover study.
- Trial name
- NCT03822520
- Testing
- Celecoxib, Moxifloxacin, Water
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Healthy Volunteer
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
- Trial name
- NCT07378579
- Testing
- ESK-001, Moxifloxacin (400 mg)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Alumis Inc
Healthy
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
- Trial name
- ATX-101-11-24 (NCT01706679)
- Testing
- ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg)
- Where
- United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults
The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
- Trial name
- NCT07470177
- Testing
- JMKX003142 tablets
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval…
- Trial name
- NCT01790087
- Testing
- ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Mast Therapeutics, Inc.
Healthy
A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers
A phase 1, 6-sequence, 3-period, subject- and investigator blinded and sponsor-open, crossover study in healthy volunteers to evaluate the PF-06700841 effect on QTc interval.
- Trial name
- NCT03656952
- Testing
- PF-06700841, moxifloxacin
- Where
- Belgium
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Cardiac Safety Evaluation of P03277
The study is a Phase I, Single center, Randomized, Cross-over Double-blind Placebo-controlled and Open-label Positive-controlled (moxifloxacin) in healthy volunteers.
- Trial name
- NCT03657264
- Testing
- P03277 0.1 mmol/kg, Moxifloxacin 400mg, NaCl 0.9%
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guerbet
RSV Infection, QTc Interval
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
- Trial name
- NCT06601192
- Testing
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Healthy Volunteers
A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects
This is a Thorough QT study intended to estimate the effect of glasdegib at therapeutic exposure and at supra-therapeutic exposure on cardiac repolarization in healthy subjects.
- Trial name
- B1371023 (NCT03162900)
- Testing
- Glasdegib Therapeutic Exposure, Glasdegib Supra-therapeutic Exposure, Positive Control (Moxifloxacin)
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of SNAC on cardiac repolarisation in healthy male subjects
- Trial name
- NCT02911870
- Testing
- SNAC, Moxifloxacin
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Asthma
To Investigate the Effects of AZD1981 on the QT Interval
The purpose of this research study is to evaluate the effect of AZD1981 on the electrical activity of the heart, in particular when the heart muscle is relaxed during a heart beat cycle.
- Trial name
- NCT01265641
- Testing
- AZD1981, 2000mg, AZD1981, 200mg, Moxifloxacin, 400mg
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ventricular Repolarization
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay…
- Trial name
- NCT01812538
- Testing
- DIC075V
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Electrocardiography
A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
The primary objective of this study is to evaluate the effects of therapeutic and supratherapeutic doses of avacopan on the heart rate corrected QT interval, using Fridericia's formula (QTcF).
- Trial name
- NCT05988034
- Testing
- Avacopan, Moxifloxacin
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Amgen
Malaria, Vivax
Tafenoquine Thorough QTc Study in Healthy Subjects
This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups.
- Trial name
- NCT01928914
- Testing
- Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
- Trial name
- NCT04560816
- Testing
- ALXN1840, Moxifloxacin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Healthy Volunteers
Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
This was a single-center, multiple-dose, randomized, double-blind, placebo-controlled, positive-controlled, twelve sequence, 3-period cross-over study to investigate the effect of balovaptan on the QTc interval in healthy…
- Trial name
- NCT03808298
- Testing
- Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
The main aim of this study is to find out how more than one dose of TAK-279 changes the heart-rate corrected QT (QTc) interval of healthy adults.
- Trial name
- NCT06258265
- Testing
- TAK-279, Moxifloxacin
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Takeda
Amyotrophic Lateral Sclerosis
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT01511029
- Testing
- Dexpramipexole, Moxifloxacin
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Solid Tumors
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under…
- Trial name
- NCT03258515
- Testing
- AZD6094 200 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions
The purpose of this study is to evaluate the effect of an 800-mg single dose of TMC207 on the QT/QTc interval in healthy volunteers.
- Trial name
- NCT01291563
- Testing
- Moxifloxacin, TMC207
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA